OTCMKTS:KHTRF Knight Therapeutics - KHTRF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.90 0.00 (0.00%) (As of 02/7/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.90▼$3.9050-Day Range$3.80▼$4.0652-Week Range$3.79▼$4.77VolumeN/AAverage Volume2,445 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$6.55 ProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest About Knight Therapeutics (OTCMKTS:KHTRF) StockKnight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its products include ILUVIEN, Nerlynx, Probuphine, Movantik, and Neuragen. The company was founded by Jonathan R. Goodman on November 1, 2013 and is headquartered in Montreal, Canada.Read More Receive KHTRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KHTRF Stock News HeadlinesJanuary 26, 2023 | finance.yahoo.comBerkadia Forges Alliance With Knight FrankDecember 23, 2022 | marketwatch.comKnight Therapeutics Closes $38.5 Mln Loan With International Finance Corp.February 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...December 23, 2022 | finance.yahoo.comKnight Therapeutics Closes US$38.5 million Loan with IFCNovember 13, 2022 | seekingalpha.comKnight Therapeutics Inc. (KHTRF) Q3 2022 Earnings Call TranscriptNovember 12, 2022 | finance.yahoo.comKnight Therapeutics Third Quarter 2022 Earnings: Beats ExpectationsNovember 9, 2022 | finance.yahoo.comKnight to Present at Stifel Healthcare ConferenceNovember 3, 2022 | finance.yahoo.comNotice of Knight Therapeutics' Third Quarter 2022 Results Conference CallFebruary 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…August 12, 2022 | seekingalpha.comKnight Therapeutics' (KHTRF) CEO Samira Sakhia on Q2 2022 Results - Earnings Call TranscriptAugust 12, 2022 | benzinga.comG2S2 CAPITAL INC. FILES EARLY WARNING REPORT FOR INVESTMENT IN KNIGHT THERAPEUTICS INC.July 4, 2022 | nasdaq.comKnight Therapeutics To Relaunch AKYNZEO In BrazilJune 14, 2022 | finance.yahoo.comDoes Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?May 24, 2022 | seekingalpha.comKnight Therapeutics enters license, supply pacts with RigelMay 12, 2022 | finance.yahoo.comKnight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®March 31, 2022 | finance.yahoo.comKnight Therapeutics Inc. (TSE:GUD) insiders placed bullish bets worth CA$3.1m in the last 12 monthsMarch 25, 2022 | seekingalpha.comKnight Therapeutics reports Q4 resultsMarch 17, 2022 | finance.yahoo.comNotice of Knight Therapeutics' Fourth Quarter and Year End 2021 Results Conference CallJanuary 7, 2022 | nasdaq.comKnight Therapeutics Inc (KHTRF)December 14, 2021 | finance.yahoo.comIs Knight Therapeutics (TSE:GUD) Using Too Much Debt?December 2, 2021 | finance.yahoo.comKnight to Present at Stifel GMP’s The Future of Healthcare ConferenceNovember 11, 2021 | finance.yahoo.comKnight Therapeutics Reports Third Quarter 2021September 30, 2021 | finance.yahoo.comWhat Type Of Shareholders Make Up Knight Therapeutics Inc.'s (TSE:GUD) Share Registry?September 24, 2021 | finance.yahoo.comKnight Therapeutics Inc. places No. 27 on The Globe and Mail’s third-annual ranking of Canada’s Top Growing CompaniesSeptember 23, 2021 | msn.comBRIEF-Knight Therapeutics Enters Into Exclusive Supply And Distribution Agreement With IncyteAugust 13, 2021 | markets.businessinsider.comWhat Wall Street expects from Knight Therapeutics's earningsAugust 13, 2021 | finance.yahoo.comKnight Therapeutics Reports Second Quarter 2021See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KHTRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KHTRF Company Calendar Today2/07/2023Next Earnings (Estimated)3/22/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:KHTRF CUSIPN/A CIKN/A Webwww.gud-knight.com Phone(514) 484-4483FaxN/AEmployees660Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.55 High Stock Price Forecast$7.50 Low Stock Price Forecast$5.40 Forecasted Upside/Downside+67.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesSamira SakhiaPresident, Chief Executive Officer & DirectorUtchanah ArvindChief Financial OfficerMonica PercarioVice President-Global Scientific AffairsDaniela Marino MarinoVice President-Legal and ComplianceAmal KhouriChief Business OfficerKey Competitors1933 IndustriesOTCMKTS:TGIFF4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFAcreageOTCMKTS:ACRHFView All Competitors KHTRF Stock - Frequently Asked Questions Should I buy or sell Knight Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KHTRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KHTRF, but not buy additional shares or sell existing shares. View KHTRF analyst ratings or view top-rated stocks. What is Knight Therapeutics' stock price forecast for 2023? 1 brokers have issued 12-month price objectives for Knight Therapeutics' shares. Their KHTRF share price forecasts range from $5.40 to $7.50. On average, they expect the company's stock price to reach $6.55 in the next year. This suggests a possible upside of 67.9% from the stock's current price. View analysts price targets for KHTRF or view top-rated stocks among Wall Street analysts. How have KHTRF shares performed in 2023? Knight Therapeutics' stock was trading at $3.80 at the beginning of the year. Since then, KHTRF shares have increased by 2.6% and is now trading at $3.90. View the best growth stocks for 2023 here. Are investors shorting Knight Therapeutics? Knight Therapeutics saw a decline in short interest in January. As of January 15th, there was short interest totaling 451,300 shares, a decline of 12.5% from the December 31st total of 515,700 shares. Based on an average trading volume of 2,800 shares, the days-to-cover ratio is presently 161.2 days. View Knight Therapeutics' Short Interest. When is Knight Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023. View our KHTRF earnings forecast. What is Knight Therapeutics' stock symbol? Knight Therapeutics trades on the OTCMKTS under the ticker symbol "KHTRF." How do I buy shares of Knight Therapeutics? Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Knight Therapeutics' stock price today? One share of KHTRF stock can currently be purchased for approximately $3.90. How many employees does Knight Therapeutics have? The company employs 660 workers across the globe. How can I contact Knight Therapeutics? Knight Therapeutics' mailing address is 3400 de Maisonneuve West, Montréal, QC H3Z. The official website for the company is www.gud-knight.com. The company can be reached via phone at (514) 484-4483. This page (OTCMKTS:KHTRF) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.